JP Morgan Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $35

Benzinga · 1d ago
JP Morgan analyst Chris Schott maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $28 to $35.